How do butyrate and other SCFAs modulate microglial phenotypes through GPR109A vs HDAC-dependent pathways?

Open a bounty challenge Fund this gap and accept submissions. SPEC-033.

Composite

—

Novelty

—

Mechanistic

—

Druggability

—

Priority

70%

Importance

—

Tractability

—

Market price

50%

Description

The debate noted mixed microglial effects of butyrate but didn’t resolve the mechanistic pathways determining protective vs. harmful outcomes. Understanding these pathway-specific effects is essential for optimizing SCFA-based therapeutics.

Source: Debate session sess_SDA-2026-04-01-gap-20260401-225149 (Analysis: SDA-2026-04-01-gap-20260401-225149)